DGAP-News

MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma (news with additional features) 21.07.2017 / 18:05 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, July 21, 2017

MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

Phase II Trial of Investigational Anetumab Ravtansine Did Not Meet Primary Endpoint in Patients With Advanced Pleural Mesothelioma

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its partner Bayer AG has reported that a phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural mesothelioma did not meet the primary endpoint of progression-free survival. Anetumab ravtansine is an antibody-drug conjugate (ADC) directed against mesothelin, comprising an antibody made using MorphoSys's HuCAL technology. Malignant pleural mesothelioma is a rare cancer and is commonly caused by occupational or environmental exposure to asbestos.

"The outcome of this phase 2 study with anetumab ravtansine in recurrent malignant pleural mesothelioma is disappointing, in particular for the patients suffering from this serious and extremely difficult to treat disease", said Dr. Markus Enzelberger, Interim Chief Scientific Officer of MorphoSys AG. "Nevertheless, Bayer remains committed to further evaluating the potential of this compound across multiple tumor types with significant unmet medical need. We are proud of our long-standing relationship with Bayer, and we look forward to further updates about the development program with anetumab ravtansine going forward."